Association Between Coffee Intake After Diagnosis of Colorectal Cancer and Reduced Mortality
- PMID: 29158191
- PMCID: PMC5847429
- DOI: 10.1053/j.gastro.2017.11.010
Association Between Coffee Intake After Diagnosis of Colorectal Cancer and Reduced Mortality
Abstract
Background & aims: Few studies have examined the association between coffee intake and survival after diagnosis of colorectal cancer (CRC). We performed a prospective study to investigate the association between coffee intake after a diagnosis of CRC and mortality.
Methods: We collected data from the Nurses' Health Study (1984-2012) and Health Professionals Follow-up Study (1986-2012), following 1599 patients diagnosed with stage 1, 2, or 3 CRC. CRC was reported on questionnaires and ascertained by review of medical records and pathology reports; intake of food and beverages was determined from responses to semi-quantitative food frequency questionnaires. Participants were asked how often during the previous year that they consumed coffee, with 1 cup as the standard portion size. The first questionnaire response collected at least 6 months but not more than 4 years after diagnosis was used for assessment of post-diagnostic intake (median time from diagnosis to the dietary assessment, 2.2 years). The last semi-quantitative food frequency questionnaire prior to diagnosis was used to assess pre-diagnostic dietary intake.
Results: During a median of 7.8 years of follow-up, we documented 803 deaths, of which 188 were because of CRC. In the multivariable adjusted models, compared with nondrinkers, patients who consumed at least 4 cups of coffee per day had a 52% lower risk of CRC-specific death (hazard ratio [HR] 0.48; 95% CI, 0.28-0.83; P for trend=.003) and 30% reduced risk of all-cause death (HR, 0.70; 95% CI, 0.54-0.91; P for trend <.001). High intake of caffeinated and decaffeinated coffee (2 or more cups/day) was associated with lower risk of CRC-specific mortality and all-cause mortality. When coffee intake before vs after CRC diagnosis were examined, compared with patients consistently consuming low amounts (less than 2 cups/day), those who maintained a high intake (2 or more cups/day) had a significantly lower risk of CRC-specific death (multivariable HR, 0.63; 95% CI, 0.44-0.89) and death from any cause (multivariable HR, 0.71; 95% CI, 0.60-0.85).
Conclusions: In an analysis data from the Nurses' Health Study and Health Professionals Follow-up Study, we associated intake of caffeinated and decaffeinated coffee after diagnosis of CRC with lower risk of CRC-specific death and overall death. Studies are needed to determine the mechanisms by which coffee might reduce CRC progression.
Keywords: Colon Cancer; Diet; Post-diagnostic Coffee Intake; Rectal Cancer.
Copyright © 2018 AGA Institute. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
The authors disclose no conflicts.
Figures



Comment in
-
Coffee and Colorectal Cancer: Grounds for Prevention?Gastroenterology. 2018 Mar;154(4):790-792. doi: 10.1053/j.gastro.2018.02.006. Epub 2018 Feb 6. Gastroenterology. 2018. PMID: 29425921 No abstract available.
Similar articles
-
Caffeinated and decaffeinated coffee and tea intakes and risk of colorectal cancer in a large prospective study.Am J Clin Nutr. 2012 Aug;96(2):374-81. doi: 10.3945/ajcn.111.031328. Epub 2012 Jun 13. Am J Clin Nutr. 2012. PMID: 22695871 Free PMC article.
-
Coffee, tea, and caffeine consumption and incidence of colon and rectal cancer.J Natl Cancer Inst. 2005 Feb 16;97(4):282-92. doi: 10.1093/jnci/dji039. J Natl Cancer Inst. 2005. PMID: 15713963 Free PMC article.
-
Coffee consumption and risk of colorectal cancer in the Cancer Prevention Study-II Nutrition Cohort.Cancer Epidemiol. 2020 Aug;67:101730. doi: 10.1016/j.canep.2020.101730. Epub 2020 Jun 9. Cancer Epidemiol. 2020. PMID: 32526644
-
Does drinking coffee reduce the risk of colorectal cancer? A qualitative umbrella review of systematic reviews.Tech Coloproctol. 2023 Nov;27(11):961-968. doi: 10.1007/s10151-023-02804-3. Epub 2023 May 2. Tech Coloproctol. 2023. PMID: 37129722
-
Coffee and caffeine intake and risk of ovarian cancer: a systematic review and meta-analysis.Int J Gynecol Cancer. 2019 Mar;29(3):579-584. doi: 10.1136/ijgc-2018-000102. Int J Gynecol Cancer. 2019. PMID: 30833443
Cited by
-
Association of Diet Quality With Survival Among People With Metastatic Colorectal Cancer in the Cancer and Leukemia B and Southwest Oncology Group 80405 Trial.JAMA Netw Open. 2020 Oct 1;3(10):e2023500. doi: 10.1001/jamanetworkopen.2020.23500. JAMA Netw Open. 2020. PMID: 33125497 Free PMC article.
-
Coffee and tea intake and survival of cancer patients: a systematic review and meta-analysis.Cancer Causes Control. 2025 Jul 11. doi: 10.1007/s10552-025-02033-z. Online ahead of print. Cancer Causes Control. 2025. PMID: 40643840
-
Does caffeine have a double-edged sword role in inflammation and carcinogenesis in the colon?Intest Res. 2023 Jul;21(3):306-317. doi: 10.5217/ir.2022.00118. Epub 2023 Apr 20. Intest Res. 2023. PMID: 37072923 Free PMC article. Review.
-
Variety of Fruit and Vegetables and Alcohol Intake are Associated with Gut Microbial Species and Gene Abundance in Colorectal Cancer Survivors.Am J Clin Nutr. 2023 Sep;118(3):518-529. doi: 10.1016/j.ajcnut.2023.07.011. Epub 2023 Jul 18. Am J Clin Nutr. 2023. PMID: 37474105 Free PMC article.
-
Identifying modifiable risk factors to prevent aggressive colorectal cancer.Int J Cancer. 2024 Oct 1;155(7):1191-1202. doi: 10.1002/ijc.34993. Epub 2024 May 8. Int J Cancer. 2024. PMID: 38716828
References
-
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67:7–30. - PubMed
-
- Miller KD, Siegel RL, Lin CC, et al. Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin. 2016;66:271–289. - PubMed
-
- Zgaga L, Theodoratou E, Farrington SM, et al. Plasma vitamin d concentration influences survival outcome after a diagnosis of colorectal cancer. J Clin Oncol. 2014;32:2430–9. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- R35 CA197735/CA/NCI NIH HHS/United States
- R01 CA118553/CA/NCI NIH HHS/United States
- P01 CA087969/CA/NCI NIH HHS/United States
- P30 DK043351/DK/NIDDK NIH HHS/United States
- U01 CA167552/CA/NCI NIH HHS/United States
- R01 CA137178/CA/NCI NIH HHS/United States
- K24 DK098311/DK/NIDDK NIH HHS/United States
- UM1 CA186107/CA/NCI NIH HHS/United States
- R01 CA169141/CA/NCI NIH HHS/United States
- UM1 CA167552/CA/NCI NIH HHS/United States
- P50 CA127003/CA/NCI NIH HHS/United States
- UL1 TR001863/TR/NCATS NIH HHS/United States
- R01 CA202704/CA/NCI NIH HHS/United States
- UM1 CA176726/CA/NCI NIH HHS/United States
- P01 CA055075/CA/NCI NIH HHS/United States
- R01 CA151993/CA/NCI NIH HHS/United States
- U01 CA176726/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical